NAD refers skin care claims to FDA
This article was originally published in The Tan Sheet
Executive Summary
National Advertising Division finds Pinnacle Marketing has "failed to provide any substantiating information" for its Acadia Skin Care product and has thus referred the case to FDA. In an upcoming NAD Case Report, Council of Better Business Bureaus division challenges print ads claiming Acadia "will help relieve the irritation and embarrassment of psoriasis, eczema, seborrheic dermatitis, rough, dry skin and dandruff," and that product's "active ingredients are FDA approved." In response, Pinnacle maintained claims at issue could be substantiated but said it would not do so "for economic reasons"...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.